AU2013259192B2 - Use of semaphorin-4D binding molecules to promote neurogenesis following stroke - Google Patents

Use of semaphorin-4D binding molecules to promote neurogenesis following stroke Download PDF

Info

Publication number
AU2013259192B2
AU2013259192B2 AU2013259192A AU2013259192A AU2013259192B2 AU 2013259192 B2 AU2013259192 B2 AU 2013259192B2 AU 2013259192 A AU2013259192 A AU 2013259192A AU 2013259192 A AU2013259192 A AU 2013259192A AU 2013259192 B2 AU2013259192 B2 AU 2013259192B2
Authority
AU
Australia
Prior art keywords
ser
gly
antibody
tyr
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013259192A
Other languages
English (en)
Other versions
AU2013259192A1 (en
Inventor
Ernest S. Smith
Maurice Zauderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of AU2013259192A1 publication Critical patent/AU2013259192A1/en
Application granted granted Critical
Publication of AU2013259192B2 publication Critical patent/AU2013259192B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013259192A 2012-05-11 2013-05-10 Use of semaphorin-4D binding molecules to promote neurogenesis following stroke Ceased AU2013259192B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261646119P 2012-05-11 2012-05-11
US61/646,119 2012-05-11
US13/842,523 US10494440B2 (en) 2012-05-11 2013-03-15 Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US13/842,523 2013-03-15
PCT/US2013/040661 WO2013170221A1 (en) 2012-05-11 2013-05-10 Use of semaphorin-4d binding molecules to promote neurogenesis following stroke

Publications (2)

Publication Number Publication Date
AU2013259192A1 AU2013259192A1 (en) 2014-11-27
AU2013259192B2 true AU2013259192B2 (en) 2018-02-22

Family

ID=49548777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013259192A Ceased AU2013259192B2 (en) 2012-05-11 2013-05-10 Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

Country Status (18)

Country Link
US (1) US10494440B2 (enExample)
EP (1) EP2846831B1 (enExample)
JP (1) JP6218810B2 (enExample)
KR (1) KR102105436B1 (enExample)
CN (2) CN110064054A (enExample)
AU (1) AU2013259192B2 (enExample)
BR (1) BR112014028160B1 (enExample)
CA (1) CA2872928C (enExample)
DK (1) DK2846831T3 (enExample)
EA (1) EA030796B1 (enExample)
ES (1) ES2882881T3 (enExample)
IL (1) IL235603B (enExample)
MX (1) MX358991B (enExample)
NZ (1) NZ630864A (enExample)
PT (1) PT2846831T (enExample)
SG (1) SG11201407416XA (enExample)
WO (1) WO2013170221A1 (enExample)
ZA (1) ZA201501674B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2427212T3 (enExample) 2009-05-08 2018-01-20
CN104168956A (zh) 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
BR112018071686A2 (pt) 2016-04-22 2019-02-19 Vaccinex, Inc. exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
WO2018156509A1 (en) * 2017-02-22 2018-08-30 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
CN110636858B (zh) 2017-05-05 2024-03-19 瓦西尼斯公司 人抗脑信号蛋白4d抗体
WO2024182357A1 (en) * 2023-02-28 2024-09-06 Brandeis University Compositions and methods for the chronic treatment of epilepsy and epileptogenesis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080219971A1 (en) * 2007-02-14 2008-09-11 Vaccinex, Inc. Human anti-cd100 antibodies
US20100285036A1 (en) * 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-CD100 Neutralizing Antibodies and Methods of Using the Same
US20120027758A1 (en) * 2003-01-31 2012-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-cd100 antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
RU2006124743A (ru) 2003-12-11 2008-01-20 Дженентек, Инк. (Us) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет
AU2005209331A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
JP2008504821A (ja) * 2004-07-01 2008-02-21 バイレクシス コーポレイション ベクター・パッケージング細胞系列
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
EP1871484A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Sema4d in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
WO2009089461A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
CN102421913A (zh) * 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US8834883B2 (en) 2010-06-14 2014-09-16 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
US9447191B2 (en) 2011-05-13 2016-09-20 National University Corporation Tokyo Medical And Dental University Osteogenesis promoter
CN104168956A (zh) 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2018156509A1 (en) * 2017-02-22 2018-08-30 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027758A1 (en) * 2003-01-31 2012-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-cd100 antibodies
US20080219971A1 (en) * 2007-02-14 2008-09-11 Vaccinex, Inc. Human anti-cd100 antibodies
US20100285036A1 (en) * 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-CD100 Neutralizing Antibodies and Methods of Using the Same

Also Published As

Publication number Publication date
SG11201407416XA (en) 2015-03-30
CN110064054A (zh) 2019-07-30
KR20150018555A (ko) 2015-02-23
CA2872928C (en) 2021-02-16
BR112014028160B1 (pt) 2021-01-12
KR102105436B1 (ko) 2020-04-29
EA201492067A1 (ru) 2015-05-29
JP2015517502A (ja) 2015-06-22
ZA201501674B (en) 2021-06-30
DK2846831T3 (en) 2021-10-11
CN104619341A (zh) 2015-05-13
EA030796B1 (ru) 2018-09-28
IL235603B (en) 2020-01-30
US10494440B2 (en) 2019-12-03
ES2882881T3 (es) 2021-12-03
AU2013259192A1 (en) 2014-11-27
MX358991B (es) 2018-08-31
EP2846831A4 (en) 2015-11-18
IL235603A0 (en) 2015-01-29
EP2846831A1 (en) 2015-03-18
NZ630864A (en) 2017-03-31
EP2846831B1 (en) 2021-07-07
MX2014013676A (es) 2015-02-05
PT2846831T (pt) 2021-08-19
US20130302320A1 (en) 2013-11-14
WO2013170221A1 (en) 2013-11-14
CA2872928A1 (en) 2013-11-14
JP6218810B2 (ja) 2017-10-25

Similar Documents

Publication Publication Date Title
AU2013259192B2 (en) Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
AU2021202095B2 (en) Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
US11534488B2 (en) Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
AU2018225493B2 (en) Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
US11597765B2 (en) Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
JP2025118705A (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
NZ623856B2 (en) Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired